Accepted Manuscript



Early-stage myeloid derived suppressor cell count: basophil exclusion matters

Fabrice Uhel, MD, PhD, Imane Azzaoui, PhD, Simon Le Gallou, PhD, Thierry Fest, MD, PhD, Karin Tarte, PharmD, PhD, Mikael Roussel, MD, PhD

PII: S0091-6749(19)30889-9

DOI: https://doi.org/10.1016/j.jaci.2019.06.027

Reference: YMAI 14068

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 27 December 2018

Revised Date: 27 May 2019

Accepted Date: 14 June 2019

Please cite this article as: Uhel F, Azzaoui I, Le Gallou S, Fest T, Tarte K, Roussel M, Early-stage myeloid derived suppressor cell count: basophil exclusion matters, *Journal of Allergy and Clinical Immunology* (2019), doi: https://doi.org/10.1016/j.jaci.2019.06.027.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Early-stage myeloid derived suppressor cell count: basophil exclusion matters

Fabrice Uhel, MD, PhD[a,b], Imane Azzaoui, PhD[b,c], Simon Le Gallou, PhD[b,c], Thierry Fest, MD, PhD[b,c], Karin Tarte, PharmD, PhD[b,c], and Mikael Roussel, MD, PhD[b,c]

[a] CHU de Rennes, Maladies Infectieuses et Réanimation Médicale, Rennes, France ;
[b] INSERM, UMR U1236, Université Rennes 1, EFS Bretagne, Rennes, France ;
[c] Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.

Mikael Roussel, Laboratoire Hématologie, CHU Pontchaillou, 2 rue Henri Le Guilloux, F-35033 Rennes, Tel +33 299 389 142; E-mail: mikael.roussel@chu-rennes.fr

This work was supported by a research grant from the National Institute of Cancer (INCa Recherche Translationnelle 2010), by the Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS), and by the LYSA group. MR is a recipient of a fellowship from the Nuovo-Soldati Foundation.

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interests.

ACCEPTED MANUSCRIPT

Capsule summary:

e-MDSCs, defined as Lin^{neg} (CD3/CD14/CD15/CD19/CD56) HLA-DR^{neg} $CD33^{pos}$, have a phenotype that overlaps with basophils. For a proper quantification of e-MDSCs by flow cytometry, the gating strategy should specifically exclude basophils.

Keywords:

Myeloid-derived suppressor cells, basophils, myeloid cells, flow cytometry, phenotyping

To the Editor:

Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of myeloid cells characterized by their immune suppressive functions.[1] Circulating MDSCs are increased in inflammatory diseases, sepsis,[2] and numerous cancers, including lymphoid malignancies[3] and solid tumors. Their number increases with disease severity and predicts response to treatment and overall survival in various cancers.[3,4] In septic patients, polymorphonuclear (PMN)-MDSCs are specifically associated with the occurrence of nosocomial infections.[2] Consequently, these cells are becoming important biomarkers in several clinical situations and need as such to be accurately quantified. However, despite efforts in recent years to unify the nomenclature of MDSCs, it remains difficult to standardize their gating strategy by flow cytometry because of their lack of fully specific phenotypic markers.

In human peripheral blood mononuclear cells (PBMC), monocytic (M)-MDSCs are defined as $CD14^{pos}$ HLA-DR^{low} $CD15^{neg}$ and PMN-MDSCs as $CD11b^{pos}$ $CD14^{neg}$ $CD15^{pos}$ (or $CD66b^{pos}$) low-density granulocytes.[1]. Recently, a third subset so-called early-stage subset of MDSCs (e-MDSC) comprising more immature progenitors has been identified as Lin^{neg} (CD3/CD14/CD15/CD19/CD56) HLA-DR^{neg} $CD33^{pos}$ $CD11b^{pos}$ cells lacking myeloid lineage markers of M-MDSCs and PMN-MDSCs.[1,5] The existence of e-MDSC has been

demonstrated in renal cell carcinoma, epithelial ovarian cancer, and head and neck cancer but their suppressive function remains unproven.[4,6,7]

Basophils represent 0.5-1% of peripheral leukocytes in normal conditions. They can be isolated within the PBMC fraction after a density gradient centrifugation, and are CD33^{pos} CD11b^{pos} HLA-DR^{neg} CD3^{neg} CD14^{neg} CD19^{neg} CD56^{neg}, and for the most part CD15^{neg} (i.e. Lin^{neg}).[8] Thus, their phenotype overlaps with e-MDSCs, thereby leading to potential overestimation of respective cell type counts.

To address this issue, we first analyzed peripheral blood from healthy donors (HDs, n=8) by flow cytometry using CD203c and CRTH2 antibodies ordered from Miltenyi Biotec (Bergich Gladbach, Germany), Lin-1 (CD3, CD14, CD16, CD19, CD20, CD56) from Becton Dickinson (BD Biosciences, San Jose, CA), and HLA-DR, CD33, and CD11b from Beckman Coulter (Brea, CA). We found that an average of 92.6% (range 78.5 to 98.2%) of Lin-1^{neg} HLA-DR^{neg} CD33^{pos} CD11b^{pos} cells expressed CD123 (interleukin 3 receptor α-chain) and CRTH2 (CD294, receptor for prostaglandin D2), consistently with a basophil phenotype (Figure 1A).[9] Additionally, the expression of CD203c (ecto-nucleotide pyrophosphatase phosphodiesterase, specifically expressed by basophils and mast cells upon activation) was induced on CRTH2^{pos} CD123^{pos} cells from HDs (n=3) after 15 min of stimulation by an anti-IgE antibody (Allergenicity kit, Beckman Coulter) (Figure 1B). Moreover, these cells released histamine after activation by anti-IgE, as measured by ELISA (data not shown). To confirm these findings, we sorted Lin-1^{neg} HLA-DR^{neg} CD33^{pos} CD11b^{pos} cells from a HD sample (FacsAriaIII, BD). Microscopic examination of cytospin slides stained with May-Grünwald-Giemsa and captured at 1000x magnification revealed a mixture of basophils (characterized by their large purple-black granules and double-lobed nucleus) and immature myeloid cells with agranular cytoplasm containing vacuoles (presumably e-MDSCs) (Figure 1C). Finally,

and in accordance with a previous paper,[8] we confirmed on 8 samples (n=6 HD and n=2 diffuse large B-cell lymphoma, DLBCL) that on average only 9.4% (range 4.8 to 14%) of basophils expressed CD15 (Figure 1D). Consequently, the Lin^{neg} $HLA\text{-}DR^{neg}$ $CD33^{pos}$ phenotype encompasses a vast majority of basophils, which are not excluded by the CD15 marker.

Since circulating e-MDSC are increased in various types of cancers,[4,6,7] we further analyzed 20 DLBCL samples at diagnosis from a cohort already published by our group.[3] The research protocol was conducted under French legal guidelines and fulfilled the requirements of the local institutional ethics committee; all patients provided written informed consent (BMS-LyTRANS study; clinicaltrials.gov: NCT01287923). Clinical characteristics of DLBCL patients enrolled in this cohort are listed in Table 1. Within the $Lin\text{-}1^{neg}$ $HLA\text{-}DR^{neg}$ $CD33^{pos}$ $CD11b^{pos}$ population, we defined basophils and e-MDSCs as $CD123^{pos}$ and $CD123^{neg}$ fractions, respectively (Figure 1E). Basophils represented 68.3 % (range 4.1 to 97.6 %) of $Lin\text{-}1^{neg}$ $HLA\text{-}DR^{neg}$ $CD33^{pos}CD11b^{pos}$ cells (Figure 1E).

Altogether, our results show that the Lin^{neg} $HLA\text{-}DR^{neg}$ $CD33^{pos}$ $CD11b^{pos}$ phenotype includes a heterogeneous population of functionally active mature basophils and immature myeloid cells morphologically consistent with e-MDSCs. The presence of basophils, often in large proportions, might account for the absence of clear suppressive phenotype in previous functional assays targeting e-MDSCs.[4,6,7] Therefore, in addition to the recent recommendations,[1] we suggest to include basophil-specific exclusion markers such as CRTH2/CD294 or CD123 in the reference panel, in order to refine the quantification of e-MDSCs and to better define the clinical relevance of these cells.

Fabrice Uhel, MD, PhD[a,b]
Imane Azzaoui, PhD[b,c]

Simon Le Gallou, PhD[b,c]

Thierry Fest, MD, PhD[b,c]

Karin Tarte, PhamD, PhD[b,c]

Mikael Roussel, MD, PhD[b,c]

From [a] CHU de Rennes, Maladies Infectieuses et Réanimation Médicale, Rennes, France ; [b] INSERM, UMR U1236, Université Rennes 1, EFS Bretagne, Rennes, France ; [c] Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.

The authors acknowledge Drs Patricia Amé-Thomas and Beatrice Ly-Sunnaram for their help in histamine quantification and image capture. The authors acknowledge the Centre of Ressources Biologiques of Rennes (BB-0033-00056) for managing samples. This work was supported by a research grant from the National Institute of Cancer (INCa Recherche Translationnelle 2010), the Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang, and the Lymphoma Study Association (LYSA) group.

Reference

1. Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016;7:12150.

2. Uhel F, Azzaoui I, Grégoire M, Pangault C, Dulong J, Tadie JM, et al. Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis. Am J Respir Crit Care Med 2017;196:315–27.

3. Azzaoui I, Uhel F, Rossille D, Pangault C, Dulong J, Le Priol J, et al. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood 2016;128:1081–92.

4. Lang S, Bruderek K, Kaspar C, Höing B, Kanaan O, Dominas N, et al. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets. Clin Cancer Res 2018;24:4834–44.

5. Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, et al. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. Front Immunol 2018;9:11–1.

6. Okła K, Czerwonka A, Wawruszak A, Bobiński M, Bilska M, Tarkowski R, et al. Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer. Front Immunol 2019;10:394–13.

7. Najjar YG, Rayman P, Jia X, Pavicic PG Jr, Rini BI, Tannenbaum C, et al. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α. Clin Cancer Res 2017;23:2346–55.

8. Toba K, Koike T, Shibata A, Hashimoto S, Takahashi M, Masuko M, et al. Novel technique for the direct flow cytofluorometric analysis of human basophils in unseparated blood and bone marrow, and the characterization of phenotype and peroxidase of human basophils. Cytometry A 1999;35:249–59.

9. Varricchi G, Raap U, Rivellese F, Marone G, Gibbs BF. Human mast cells and basophils-How are they similar how are they different? Immunol Rev 2018;282:8–34.

Table 1 Patients characteristics of the lymphoma cohort

Characteristics		Patients (n=20)
Average age [range] (years)		54 [32-72]
Male (n)		12
Female (n)		8
IPI (n)	0-1	6
	2	3
	3	7
	4-5	4
Cell of origin (n)	GCB	5
	Non-GCB	9
	Unknown	6

IPI: International Prognostic Index; GCB: Germinal Center B-cells

ACCEPTED MANUSCRIPT

Figure legend

Figure 1: Lin^{neg} HLA-DR^{neg} CD33^{pos} CD11b^{pos} cells contain functional basophils
A- On peripheral blood from healthy donors (HD), a subset of Lin^{neg} HLA-DR^{neg} CD33^{pos} CD11b^{pos} cells express basophil markers CD123 and CRTH2. B- Expression of CD203c on Lin^{neg} HLA-DR^{neg} CD33^{pos} CD11b^{pos} cells after anti-IgE stimulation. C- Lin^{neg} HLA-DR^{neg} CD33^{pos} CD11b^{pos} cells observed on cytospin. Basophils (▲) and mononuclear cell suggestive of e-MDSC (•). Scale bar represents 10 µm. D- Expression of CD15 on basophils (green) and neutrophils (blue). E- Lin^{neg} HLA-DR^{neg} CD33^{pos} CD11b^{pos} cells were marked as CD123^{neg} e-MDSCs (red) or CD123^{pos} basophils (green) (top panels). Significant plots from one patient are shown. Data were acquired on a Navios flow cytometer (Beckman Coulter) and analyzed with Kaluza software (Beckman Coulter).

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT